Proof that ONCY decline ROCHEThis lady added all she can... Now market missed this:
Andrew de Guttadauro:
"With several patients still receiving treatment, there is an opportunity for a truly impressive endpoint that we could sell ourselves short if we rush into a deal prematurely based on data that could improve over time.
With industry leaders such as Pfizer, Roche, Merck Serono, Bristol-Myers Squibb and Insight already familiar with pela thanks to collaborative clinical trials, we intend to run a methodical and competitive process that ensures we reach the best possible outcome for our shareholders."
Remember they are talking about survival that could improve over time.